BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
345.41
+4.17 (+1.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close341.24
Open343.10
Bid343.50 x 1100
Ask345.41 x 900
Day's Range338.52 - 345.41
52 Week Range249.17 - 388.67
Volume1,458,015
Avg. Volume1,610,546
Market Cap69.58B
Beta1.49
PE Ratio (TTM)24.52
EPS (TTM)14.08
Earnings DateOct 23, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est389.20
Trade prices are not sourced from all markets
  • MARKETS: Wall Street loves US stocks, especially health care and industrials, EMs are nearing a buy
    Yahoo Finance Video5 days ago

    MARKETS: Wall Street loves US stocks, especially health care and industrials, EMs are nearing a buy

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest moves.

  • The Wall Street Journalyesterday

    U.S. Probes Drugmakers Over Free Services

    Federal prosecutors are probing whether big drugmakers including Sanofi, Gilead Sciences and Biogen potentially violated laws by providing free services to doctors and patients.

  • What Do Analysts Recommend for Sage in September?
    Market Realist2 days ago

    What Do Analysts Recommend for Sage in September?

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company, is developing medicines for the treatment of life-altering central nervous system disorders like major depressive disorder, Parkinson’s disease, postpartum depression, and others.

  • Investopedia2 days ago

    Biogen Seen Rising 15% On Brighter Outlook

    Biogen Inc.'s ( BIIB) stock has largely disappointed investors for more than three years since it fell off its high in 2015. Earnings and revenue estimates for 2018 have increased in recent months. The company beat second-quarter estimates in July and offered better guidance. As a result, analysts now forecast earnings growth of 7% for the quarter on revenue growth of 8%.

  • 3 Drug/Biotech Stocks in Focus on World Alzheimer's Day
    Zacks2 days ago

    3 Drug/Biotech Stocks in Focus on World Alzheimer's Day

    We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.

  • The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works

    The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works

  • Top Research Reports for Wells Fargo, Schlumberger & Biogen
    Zacks3 days ago

    Top Research Reports for Wells Fargo, Schlumberger & Biogen

    Top Research Reports for Wells Fargo, Schlumberger & Biogen

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • 3 High-Quality Biotech Companies for 4th Quarter
    GuruFocus.com5 days ago

    3 High-Quality Biotech Companies for 4th Quarter

    On Monday, GuruFocus' High Quality Screener listed three biotechnology companies that offer good potential ahead of the fourth quarter: Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NVO). Warning! GuruFocus has detected 4 Warning Signs with ORCL. Berkshire Hathaway Inc. (BRK-A)(BRK-B) CEO Warren Buffett (Trades, Portfolio) has stressed several times that key investing criteria include predictable earnings and strong economic moat.

  • Better Buy: Celgene Corp. vs. Biogen
    Motley Fool6 days ago

    Better Buy: Celgene Corp. vs. Biogen

    These top biotechs have entirely different philosophies when it comes to pipeline development.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • What Solid Biosciences’ Valuation Trend Indicates
    Market Realist9 days ago

    What Solid Biosciences’ Valuation Trend Indicates

    Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.

  • Why Analysts Remain Bullish on Sangamo Therapeutics
    Market Realist10 days ago

    Why Analysts Remain Bullish on Sangamo Therapeutics

    Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.

  • Better Buy: Gilead Sciences, Inc. vs. Biogen
    Motley Fool10 days ago

    Better Buy: Gilead Sciences, Inc. vs. Biogen

    Which biotech behemoth will come out on top in a head-to-head contest?

  • Biogen Begins Phase III Study on Ischemic Stroke Candidate
    Zacks17 days ago

    Biogen Begins Phase III Study on Ischemic Stroke Candidate

    Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.

  • GlobeNewswire19 days ago

    Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction

    CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment options Prior studies ...

  • American City Business Journals19 days ago

    What you missed on your summer vacation in Mass. biotech news

    Here's a look at the Boston biotech news you missed during your summer vacation: Alnylam gets historic FDA approval for first drug Cambridge's Alnylam Pharmaceuticals (Nasdaq: ALNY) received FDA approval for its first drug on Aug. 10, a first-ever treatment for a rare genetic disease that uses RNA interference to silence genes. The drug treats hereditary ATTR amyloidosis, which causes the liver to protein abnormal proteins that impede nervous system and organ functions. Marketed under the name Onpattro, it's the first RNA interference drug to be approved by the FDA.

  • ETF Trends22 days ago

    Biotech Fund Flows, Including ETF Activity, Remain a Driver to Watch

    The biotech sector performed well in August, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) up almost 3.5% this week alone. Research by Raymond James indicates that in just the past week, biotech ...

  • How BioMarin Pharmaceutical Is Positioned Financially in August
    Market Realist22 days ago

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017, reflecting a ~17% YoY (year-over-year) growth. It reported net revenues of $746.3 million in the first half of 2018 compared to $621.2 million in the first half of 2017, reflecting a ~2% YoY growth.

  • How Analysts View BioMarin Pharmaceutical in August
    Market Realist23 days ago

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, BioMarin Pharmaceutical (BMRN) stock closed at $99.26, which is ~7% below its 52-week high of $106.20 on August 2. It hit its 52-week low of $75.81 on April 6. 

  • Benzinga25 days ago

    The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on Aug. 28) Abbott Laboratories (NYSE: ABT ) Affimed NV (NASDAQ: AFMD )(announced ...

  • US Moat Index Outperforms S&P 500 despite IT Underweight
    Market Realist26 days ago

    US Moat Index Outperforms S&P 500 despite IT Underweight

    The U.S. Moat Index posted strong performance again in July, and by the end of the month, its year-to-date results overtook the S&P 500 Index despite being underweight to the information technology sector. The U.S. Moat Index has been overweight healthcare companies for some time now as a result of the valuation dynamics in the sector. That positioning paid off in July with the top five performing constituents all coming from the sector.

  • GlobeNewswire26 days ago

    Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

    CAMBRIDGE, Mass., Aug. 28, 2018-- Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1 b study of aducanumab, an investigational treatment for ...

  • Gene Editing is a Major Technology to Watch
    InvestorPlace27 days ago

    Gene Editing is a Major Technology to Watch

    Over the last six years, a small group of scientists working at different institutes have made incredible progress in a revolutionary new field called gene editing. Gene editing is just what it sounds like. It’s the changing — or “editing” — of an organism’s genes to produce a desired outcome.

  • Ocrevus Could Boost Roche’s Revenue Growth in 2018 and Beyond
    Market Realist27 days ago

    Ocrevus Could Boost Roche’s Revenue Growth in 2018 and Beyond

    Roche’s (RHHBY) Neurology segment generated revenues of 1.38 billion Swiss francs in the first half compared to 526.0 million Swiss francs in the first half of 2017, reflecting ~164% YoY (year-over-year) growth at CER (constant exchange rates). Roche’s neuroscience portfolio includes Ocrevus and Madopar.